France has identified its first-ever case of Ebola virus disease on national territory, marking the first detection of the current outbreak outside the African continent. The patient, a doctor who had been working with the medical NGO ALIMA in the Democratic Republic of the Congo, was isolated immediately upon arrival in Paris and is in a stable condition with a very low viral load, the French health ministry said on Wednesday. The World Health Organization (WHO) assessed that the global public health risk remains low, while warning against overreaction.

The doctor boarded a commercial Air France flight from Kinshasa on Tuesday, presenting with headaches but otherwise almost asymptomatic. His condition deteriorated slightly during the journey, prompting isolation and transfer to a specialist infectious-disease unit under negative-pressure protocols even before laboratory confirmation. French authorities have launched an epidemiological investigation to trace contacts; five fellow passengers were identified and placed in precautionary isolation. The airline provided the passenger manifest to health officials, and the prime minister’s office said it was monitoring the situation very closely.

The case is linked to the 17th Ebola outbreak in DR Congo, declared on 15 May in the mineral-rich but conflict-affected Ituri province. The outbreak is driven by the rare Bundibugyo strain of the virus, for which no approved vaccine or specific treatment exists. Existing Ebola vaccines, developed for the Zaire strain, are ineffective against this variant. According to the latest official figures, more than 1,000 cases have been recorded in DR Congo, including 267 deaths, and neighbouring Uganda has confirmed 20 cases and two fatalities. The WHO assesses the public health risk as very high for DR Congo, high for bordering countries, and low for the rest of the world. Experts note that the virus was likely circulating undetected for weeks before the official declaration, and the true scale of the outbreak may be underestimated due to its concentration in remote, insecure areas.

In DR Congo, the response has been complicated by armed conflict and community resistance, with almost 80 health workers infected. The WHO announced that a clinical trial of two experimental therapies—the monoclonal antibody MBP134 and the antiviral remdesivir—will begin next week in Ituri province, potentially involving 500 to 1,000 participants. In France, contacts of the patient will undergo 21 days of home isolation and medical surveillance, the maximum incubation period. The European Centre for Disease Prevention and Control has judged the risk of infection for European residents and travellers to active transmission zones as low, and very low for the general European population.